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With the increasing emphasis on photocoagulation therapy in diabetic retinopathy, its potentials
and, most probably, the beneficial effects such therapeutic modality may have in arresting or even
improving diabetic retinopathy, one should realize
the limitations, the present lack of factual knowledge, and the theories underlying such treatment.
One should also keep in mind that light-including laser-coagulation of the retina is still employed
selectively in quite a number of other pathological
fundus conditions with time-proven effectiveness
though it no longer receives the same wide general
attention that its use in diabetic retinopathy receives today. Other ocular conditions exist, however, where investigators and practitioners in the
field of ophthalmology differ strongly in their opinions as to the efficacy of this therapeutic tool, and
even to the advisability of its use, for example,
chorioretinal malignant tumors.
Much overemphasis has been placed on the use
of laser in clinical retinal photocoagulation over the
already established "white light source," a high pressure Xenon arc lamp, as employed in the Zeiss
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Photocoagulator. However, the latter is as useful today as it has been for over a decade prior to the
invention of lasers. Of the many hundreds of laser
sources now developed, only the solid state pulsed
Ruby laser and the Argon gas laser-either with a
continuous wave (CW) or in a pulsed operationhave, as of now, found wide utilization in clinical
ophthalmology. Their use, sometimes in combination with the "white light" coagulator, add to our
therapeutic armamentarium in certain clinical situations.
Figure 1 shows diagrammatically the spectral
emission of the Xenon arc coagulator and the narrow band emissions within the visible, near ultraviolet (UV) and near infrared (IR) ranges of
various lasers which are primarily of ophthalmological interest. Of those, the Ruby laser light is of a
deep red color (.\. 694.3 nm), and the Argon laser
has several bands of spectral emission primarily in
the blue-green region (A. 485-515 nm). Figure 2
presents the absorption characteristics of the retinal
pigment epithelium and choroid for light of equal
intensity and incident on the cornea.
The Ruby laser, usually operated in a single
pulse mode in the microsecond range, and the
variable retinal image diameter of the laser beam
289
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Fig. I-Spectral position of light emitted from various laser
sources in comparison with emission characteristics of a
Xeqon high-pressure light source.

of about 100-500 µ have proven to be of particular
value in the treatment of small lesions close to the
macula. The dark red color of the emitted laser
beam allows for treatment without retrobulbar
anesthesia, since in this spectral range no photophobia is elicited, and the eye has "no time to move"
during the short exposure time. On the other hand,
light of this wavelength is greatly reflected by the
red blood vessels and only minimally absorbed by
them, which makes it less usable for coagulation of
vascular lesions. If those are located within the
retina, the heat generated by absorption of the light
in the retinal pigment epithelium may secondarily
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Fig. 2-Percent absorption in human retinal pigment epithelium and choroid for equal intensities and light incident on
the cornea. Ar
Main Argon laser emission bands. R
Ruby laser wavelength.
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cause vessel obliteration. In cases where vessel proliferation into the vitreous h as developed, as seen
primarily in diabetic retinopathy (fig. 3) am?ng
other pathological conditions, the Ruby laser hght
is relatively ineffective and may even be hazardous
if the light energy is increased to achieve coagul.ation of vascular structures within the vitreous itself (7). This is the area where the Argon laser
has found its principal and dominant role in clinical ophthalmology. The bright bluish-green laser
beam produces photophobia similar to white light
and, thus, in most situations retrobulbar ')nesthesia is required . This spectral wavelength is strongly
absorbed by the hemoglobin and achieves coagulation of the blood with vascular obliteration most
easily and successfully ( 6, 9).
.
In early stages of diabetic retinopathy with
retinal microaneurysms, hemorrhages, and exudates
(figs. 4 and 5) , and in more advanced stages where
neovascularization has already developed (fig. 6),
both white light and Argon laser light are equally
effective. Only in conditions where the lesiJns are
close to the macula is the Argon laser superior since
its greater light intensity permits retinal coagulation
of very small foci, thus creating a condition of less
potential danger to the macula and fovea.
More recently, Blair and Gass (2) showed that
"mild photocoagulation" in the area of the maculopapillar bundle did not produce large central scotomata due to destruction of nerve fibers passing over
the coagulated site to the optic nerve. This observation had been described in animal experimentation
using histological techniques at various time intervals following light exposure (7), and in human
volunteers whose eyes had to be enucleated for
other pathological reasons ( 8).
The effectiveness of photocoagulation in diabetic retinopathy has not been statistically established on a large scale. Its evaluation is difficult
since the natural pathological condition may frequently undergo periods of arrested states or even
improvement. It is, therefore, not astonishing that
a number of ophthalmologists are not in favor of
this relatively destructive form of therapy. Proponents for photocoagulation therapy can be largely
separated into two groups, that is, 1) those who
prefer to coagulate only those lesions which may
potentially cause vitreous hemorrhages and areas of
neovascularization; and 2) those who want to therapeutically produce large chorioretinal scars involving areas of diseased and ophthalmoscopically
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Fig. 3a-Massive vascular proliferation.

Fig. 3c-Moderate glial proliferation.

Fig. 3b-Glial and vascular proliferation.

Fig. 3d-Extensive glial proliferation.

normal-appearing retinal tissue as well. The latter
concept is based on certain naturally occurring pathological processes involving the eye which have
seemingly prevented the development of diabetic
retinopathy or at least have retarded its progression
to a significant degree.
Such conditions have been described in eyes
with severe glaucomatous optic atrophy, severe
myopia, conditions with decreased retinal arterial
blood supply, retinitis pigmentosa, large chorioretinal

scars following inflammatory reactions, and so forth.
In many of the latter instances, the disease was
present unilaterally with the fellow eye serving as a
control. Hence, production of similar large chorioretinal scars with photocoagulation was expected to
create a similar arrest of the progressing stages of
diabetic retinopathy by way of reducing retinal blood
supply as is common in all of the above mentioned
disease entities.
However, regardless of whether one follows
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Fig. 4-Retinal hemorrhages, few exudates, and microaneurysms.

Fig. 5-Hard exudates with some new vessel formation at
the optic disc.

the more conservative and restricted application,
as we do, or the more aggressive approach, photocoagulation therapy of diabetic retinopathy seems
presently to be the most effective of all therapeutic
attempts to bring this disease process under control. It is at the same time considered relatively safe
as measured by experiences and data collected over
the last 10 years with many hundreds of patients
treated in this fashion. Also, in contrast to the
surgical approach of pituitary ablation , the general
state of the diabetic patient is not affected by photocoagulation. Pituitary ablation was amenable only
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to patients who had no other organs involved to
any measurable extent, one eye having already become practically blind with the fellow eye still having
useful visual acuity, and where the patients' background allowed for a continuous controlled medical
substitute therapy throughout the remainder of their
lives.
As to the prognosis of photocoagulation therapy,
it is generally believed that its greatest beneficial
results can be expected if treatment is provided in
the early stages of the retinopathy before vasoproliferation takes place. In many cases of macular
edema with reduced vision and in cases of extensive
retinal exudates, flucirescein angiography allows
visualization of vascular leakage which can then be
effectively sealed off by coagulation treatment. However, this appears not to be the only mechanism
involved in the further prevention of retinal edema.
Peyman and Bok ( 12) have shown in peroxidase
diffusion studies in the normal and laser-coagulated
retina of primate retinae that the normal barrier at
the site of tight junctions of the pigment epithelium
broke down at the site of the coagulation. This allowed intercellular peroxidase diffusion to take
place across the original junctional barrier in both
directions, that is, from the choriocapillaries to the
retina and vice versa. However, diffusion in the
retina-to-choroid direction was more extensive than
chorioretinal diffusion. The investigators concluded
from these observations that the breakdown of the
junctional complexes of the retinal pigment epithelium in addition to the alterations in the permeability
of the choriocapillaries account for the disappearance · of sub- and intraretinal fluid after photocoagulation treatment.
Severe vascular proliferation treated with the
Argon laser is at present still experimental and its
lasting effect is still questionable. However, in those
conditions with extremely poor visual prognosis,
photocoagulation as well as the more recent surgical attempts ( 1) seem to be warranted.
It should, again, be re-emphasized that light
coagulation therapy in diabetic retinopathy is still
debated as to its efficacy. If effective, it appears that
treatment of early stages is more amenable and the
response more successful. This possible success is
somewhat interfered with by the delay in which the
patient is referred for coagulation treatment. This
understandable hesitation in subjecting the patient to
a not firmly established certain form of therapy may
lead on the other hand to more severe grades of the
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retinopathy which are much more questionable in
their response to photocoagulation.
Other therapeutic approaches using hormones,
vitamins, anticoagulants, calcium, aminoacids, lipotropic substances, arttimetabolites, and so forth,
have not provided a controlling effect on the progression of diabetic retinopathy. Recently, attention has
again been focused on the possible beneficial action
of salicylic acid on the development and progression
of this retinal pathology. Carroll and Geeraets ( 3)
reported clinical observations based on diabetic patients on long-term salicylic acid intake vs. those
without or with only occasional intake of this
medication. Their statistical evaluation seemed to
prove a significantly lower grade of retinopathy in
the former. Findings of Dobbie et al. ( 4) seem to
support this. They advanced the theory by which
salicylates interact with the progression of the retinopathy by the prevention of platelet coagulation
due to an abnormal aggregation-enhancing plasma
factor in diabetes. Such relatively simple chemotherapy should, therefore, be more closely examined as to its effectiveness under controlled conditions and in a relatively large patient population.
In the apparently effective low dose in which salicylates would have to be prescribed, other side effects, that is, gastrointestinal hemorrhages, would not
be expected. Caution would, however, be indicated
in hepatic disease, hypoprothrombinemia, hemophilia, vitamin K deficiency, and other hemorrhagic
diseases in association with diabetes. However, controlled studies of drugs in humans have been almost
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Fig. 6-(Top left) Fine exudates, retinal hemorrhages, and
early neovascularization; (Top and bottom right) Early
vasoproliferation with neovascularization, hemorrhages, and
fine exudates.

impossible because of the random occurrence, random progression, and irregular and unpredictable
incidence of spontaneous remissions.
In recent years many authors have stressed that
therapy in diabetic retinopathy cannot be successfully accomplished until adequate experimental animal models have been produced to study the various ramifications of the disease, including controlled
drug studies. Although diabetic retinopathy in
animals has been successfully produced ( 5), these
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time consuming and very costly experiments have
left the question unanswered as to the similarity of
the pathogenesis of the retinopathy and, hence,
whether it is comparable to human diabetic retinopathy. Heath ( 10) reported a literature review on
this topic in 1970.
In previous efforts to study diabetic retinopathy
in experimental animals, only two forms have been
available: 1) animals with spontaneous diabetes
which were kept alive and were bred for further
observation, progression of the disease and its ocular
complications, and its genetic implications in producing the disease in the offspring; 2) animals which were
made artificially diabetic with alloxan or growth
hormone, and their clinical status was followed
under strict observation for possible development of
diabetic retinopathy. The only variation in these
two basic approaches has been to vary the degree
of diabetic control.
Several important metabolic characteristics of
retinas in human and animal diabetics have been
ascertained in recent years:
1) increased lactate levels
2) increased C0 2 levels
3) increased glucose levels (higher than in the
general circulation and insulin resistant)
4) increased lactic dehydrogenase activity
That the increased lactate level may be a
direct stimulant to abnormal vascular changes was
suggested by Imre's work ( 11) in which he produced
intravitreal neovascularization in the eyes of kittens
by injecting 0.1 % lactic acid into the vitreous
body.
In addition to the abnormal metabolic processes in diabetic retinas and the premise that these
may produce the abnormal vascular ch anges, it is
also now under consideration whether abnormal
antigen-antibody reactions may be one of the etiologic factors in initiating the vascular changes. The
insulin inhibitor may be the antigen in this abnormal immunological response, and increased capillary permeability caused by this reaction may be the
initial process in the vascular changes. Abnormal
metabolites might also act as antigens.
In addition to the present knowledge about
the metabolic abnormalities in diabetic retinopathy,
there is also some evidence about the changes occurring in retinitis pigmentosa which apparently
prevent the development of diabetic retinopathy.
In this disease, taurine is reduced in amount; ~-
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aminoisobutyric acid is reduced in concentration ;
and there is a reduction in anaerobic glycolysis
which can be reversed by giving pyruvate. One
could speculate that by increasing these factors,
diabetic retinopathy could be enhanced as well.
With this increasing knowledge of the pathological state of the retinal biochemistry, new chemotherapeutic agents may be developed and investigated.
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